Back to News
Oct 16, 2025 4:00 PM

Analyst Sees Noise In Q3 P&L, Affirms Abbott's Medtech Strength

Abbott Laboratories (NYSE:ABT) reported muted sales in the third quarter on Wednesday and narrowed its fiscal 2025 guidance.

The company reported third-quarter sales of $11.37 billion, slightly missing the consensus of $11.40 billion.

Abbott narrowed its fiscal 2025 adjusted earnings guidance from $5.10 to $5.20 per share to $5.12 to $5.18, compared to the consensus of $5.15 per share.

William Blair says, “Together, a somewhat noisy P&L statement led shares to trade lower.”

Analyst Brandon Vazquez stated on Wednesday that “We view these moving pieces largely as noise and believe 2026's 10% EPS growth leaves ABT in a strong position in medtech.”

Key growth drivers heading into 2026 include easing over $1 billion in diagnostics ...